The Shanghai the Jiangxia blood Technical Co., Ltd. specializes in the the blood treatment technology research and development, industrialization and knowledge of marketing, a wholly foreign-owned high-tech enterprises, Hong Kong invested. Incorporated in 2001 in the Shanghai Zhangjiang Hi-Tech Venture Park, the existing registered capital of $ 3 million, is wholly owned by the Levin liters of blood and Technology Development Co., Ltd., and in 2003 entered into a strategic partnership with the U.S. 3M, August III medical equipment production license (Shanghai drug possession of firearms production license No. 20030881) and by type testing and Technology Achievement Award. In 2004, the company obtained a high-tech transformation project certification by SFDA approved product registration card. 2008 plasma lipids in vitro adsorption filter product registration card. Independent development of blood Jiangxia vitro plasma lipids filter-JX-DELPTM, with independent intellectual property rights, utility model patents were the People's Republic of China (Patent No. ZL 200,420,021,636.6) hyperlipidemia and hyperviscosity crowd new ways of effective treatment, lipid-lowering viscosity reduction is safe and effective, convenient and economical, to make up for the shortcomings of the traditional lipid-lowering drugs and other in vitro lipid-lowering method, particularly suitable for promotion in the Chinese market, to fill the gaps. The JX-DELPTM After lasted more than three years of basic research (live animal experiments) and clinical sample observation (Huashan Hospital, Fudan University and Second Medical University Affiliated Xinhua Hospital) confirmatory therapy exact, safe and effective. The Jiangxia blood in 2007 16 joint national clinical base hospital, JX-DELPTM clinical study of a large sample of ischemic stroke. Confirmed the results of clinical studies, JX-DELPTM satisfactory treatment of ischemic stroke, large-scale clinical application. For the Shanghai the Jiangxia blood Technical Co., Ltd. will JX-DELPTM beginning to seize market opportunities, the full range of to start blood technology products in the Chinese market operators, and strive to rapid growth in product sales revenue and net profit in the next three years, in order to establish in China extracorporeal blood treatment technology market leadership, and ultimately to achieve the overall objective of the long-term sustainability. In vitro plasma lipid adsorption filters: a new tool for the prevention and treatment of ischemic stroke, independent research and development and production by Shanghai jiangxia blood Technology Co., Ltd., through the the DELP treatment system to improve the rheology, increase cerebral blood flow and save ischemic penumbra prevent thrombosis progress to prevent further embolization, purify the blood reaches the purpose of the prevention and treatment of 15 hospitals nationwide clinical trial reports, has a good safety and efficacy!